Nolimit is fabricating a news now for syringe cap. Will say that the syriinge cap is 8X the cost of normal cap that is sold in Ah Peng pharmacy.

When is Bioholding producing the respiration booster medicine? Is it in the market now?

The big question is whether K1 is producing RT-PCR swabs or some other nasal swabs? I find everywhere and the only literature I could see is 3D printed swabs by K1. This part is confusing, there is no mention of the word RT-PCR. So anyone can clarify this matter? Thanks in advance.

Thanks a lot, gwiyomi. Hopefully what K1 producing can laku. Or else, down the drain. Hopefully some orders for K1 comes in.

What type of Nasal swab is K1 producing? Is it the RT polymerase one? Not very clear on this.

Ha ha today I want to buy 2050 in K(1)uda.

Ginduchti said got news on Wednesday. Now he says political problem. You mean, due to political problem the news had been cancelled??

Looks like change of operator. This operator could not perform. Getting out by selling to the other at 8.5cents.

Ginduchti, when will the news be out? Any idea,?

7.2 point lah, not 72. May be tmrow.

Looks like directors selling down.

Ginduchti, you are very chun. You told exactly. The news out today. Sooo perfect lah you. Fantastic. What could be the next week news? Contract award from Bomba to manufacture fire related machinaries?
Mind to share. Out of 1000, one person is giving a right info. Keep it up. Cheers.
Thank you.

CME Health, one of their group.

https://www.klsescreener.com/v2/announcements/view/3230271

https://www.klsescreener.com/v2/announcements/view/3230271

https://www.klsescreener.com/v2/announcements/view/3230271

The announcement made by CME.

The Board of Directors of CME ("Board") wishes to announce that its wholly-owned subsidiary, CME Health Sdn Bhd (“CMEH”) had on17 September 2020 entered into a Collaborative Agreement (“Agreement”) with Bioalpha International Sdn Bhd (“BISB”) for BISB to develop, manufacture and supply health food supplement that aims to improve overall immunity and strengthen respiratory systems (“Product”) for CMEH to market exclusively in the South East Asia region.

In Bio Holdings. Why the other part is not appearing. Must do some maths.

Sadly he is appearing only as one person as nolimitrade.

Director said nasal production in place. Do you think they produce and keep it till expiry in the factory or lab?
Does this make sense?

Added and averaged.

I bought 100,000 at 39.5 cents. Company is promising.

Calculate the time by maths how much time you guys are spending for a hopeless stock as alleged. Day and night.Why so possessed and obsessed by K1?

Yes, there is fund to run a snap election, politics. Think twice, and do your calculation.

https://www.theedgemarkets.com/article/buy-malaysian-drive-timely-boost-covidhit-economy?type=malaysia

Buatan Malaysia. Malaysia Boleh

Imminent purchase order from MOH coming week. Be patient. Don’t simply throw your shares.

https://www.theedgemarkets.com/article/200-more-fire-and-rescue-stations-be-built-nationwide?type=malaysia

Uptrend intact for globe counters in the coming week. Malaysia constitutes 65% of world production meanwhile vaccine Hope faces hiccups.

SUNGAI BESAR (Sept 12): Results of the Covid-19 test on 366,787 residents in Kota Setar, Kedah, which is under the administrative Enhanced Movement Control Order (EMCO), are expected to take seven days to be out.

As such, Deputy Health Minister 1 Datuk Dr Noor Azmi Ghazali (pictured) urged all residents to cooperate and go to the nearest health clinic for screening, to achieve the seven-day target.

Why is this 7 days and not done by rentashealth in 3 days?

It’s fuming but cannot start off due to Bursa condition. In bad market, sellers overtake buyers if price goes up. So wait for a good green stable market.

Very aggressive actually in the past week. But could not catch up due to bad market sentiment.

Will it be in favor for K1?

U.S. Scraps Philips Ventilator Order in 2020 Earnings Blow

By Reuters
Aug. 31, 2020
Updated 4:39 a.m. ET

AMSTERDAM — Philips said the U.S. Department of Health had cancelled most of an order for 43,000 ventilators, leading the Dutch medical equipment maker to cut its 2020 earnings outlook.

The termination follows a July report by the U.S. Congress House Subcommittee on Economic and Consumer Policy that found the White House had overpaid Philips by at least $500 million. Philips denied any profiteering on ventilators.

Philips was one of several firms contracted by the U.S. to supply 187,000 ventilators to the strategic national stockpile to treat patients affected by COVID-19.

It expanded capacity in Pennsylvania and California to meet sudden demand but said in a statement on Monday that it will now deliver just 12,300 hospital ventilators by the end of the year to the U.S. Department of Health and Human services.